C21 Investments Inc

What they do

C21 Investments Inc. is a foreign private issuer incorporated in British Columbia, Canada, with principal offices in Vancouver. The company operates in the cannabis industry and its financial statements are prepared under U.S. GAAP. The filing describes the business as involving cultivation, production and dispensary operations, with references to brands and products. All dollar amounts in the annual report are in United States dollars unless otherwise indicated.

Revenue drivers

• Cannabis operations — The company's revenue is generated from its cannabis business, which the filing describes as involving cultivation, production facilities and dispensaries. The annual report discusses development and distribution of the company's brands and products as part of its activities. No further segment-level revenue breakdown is provided in the excerpt.

Recent performance

For fiscal year 2026 (ended March 31, 2026), revenue was $32.6 million, up from $30.1 million in fiscal 2025. Net loss was $3.2 million in fiscal 2026, compared with a net loss of $4.0 million in fiscal 2025. Operating cash flow was $1.4 million in fiscal 2026, unchanged from $1.4 million in fiscal 2025. At March 31, 2026, total assets were $54.4 million, total liabilities were $29.0 million and shareholder equity was $25.4 million. Diluted loss per share was $0.03 in fiscal 2026, the same as fiscal 2025.

Strategy

The annual report describes contemplated acquisitions or dispositions and the potential number and location of cultivation and production facilities and dispensaries or licenses to be acquired or sold. It also references expansion into additional U.S. and international markets and development and distribution of the company's brands and products. Management discusses expectations regarding market size and growth in the United States and in states where the company operates or contemplates future operations. The filing notes potential future legalization of adult-use and/or medical cannabis under U.S. federal law as a factor. No specific new capital investment or acquisition terms are disclosed in the excerpt.

Risks

• Regulatory and legalization uncertainty — The filing cites potential future legalization of adult-use and/or medical cannabis under U.S. federal law as a forward-looking factor, indicating regulatory change is uncertain.
• Acquisition and disposition execution — The company references contemplated acquisitions or dispositions, with uncertainty as to whether proposed transactions will be consummated on current terms or otherwise.
• Market and competitive factors — Management cites expectations for economic, business, regulatory and competitive factors related to the company and the cannabis industry generally as forward-looking considerations.
• Net losses — The company reported net losses of $3.3 million, $4.0 million and $3.2 million in fiscal 2024, 2025 and 2026, respectively.

Outlook

The filing states that forward-looking statements address activities, events or developments the company expects or anticipates will or may occur in the future. Management's outlook includes expectations regarding acquisitions or dispositions, cultivation and production capacity, brand and product distribution, and expansion into additional U.S. and international markets. It also references expectations of market size and growth in the United States and in states where the company operates or contemplates operations. The company cautions that actual results may differ materially from forward-looking statements.